Organon & Co. (NYSE:OGN) Announces $0.28 Quarterly Dividend

Organon & Co. (NYSE:OGN - Get Free Report) declared a quarterly dividend on Thursday, October 31st, Zacks reports. Shareholders of record on Tuesday, November 12th will be given a dividend of 0.28 per share on Thursday, December 12th. This represents a $1.12 dividend on an annualized basis and a yield of 6.19%. The ex-dividend date of this dividend is Tuesday, November 12th.

Organon & Co. has a payout ratio of 24.8% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Organon & Co. to earn $4.18 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 26.8%.

Organon & Co. Trading Down 3.7 %

Shares of OGN traded down $0.70 during trading on Friday, reaching $18.08. 2,701,695 shares of the company traded hands, compared to its average volume of 2,182,331. The stock has a 50-day simple moving average of $19.38 and a 200-day simple moving average of $20.10. The stock has a market cap of $4.66 billion, a PE ratio of 4.65, a price-to-earnings-growth ratio of 0.81 and a beta of 0.84. Organon & Co. has a twelve month low of $10.84 and a twelve month high of $23.10. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.04. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The company had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.61 billion. During the same quarter in the previous year, the company earned $1.31 earnings per share. The firm's quarterly revenue was down .1% compared to the same quarter last year. On average, analysts anticipate that Organon & Co. will post 4.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on OGN shares. Evercore ISI raised Organon & Co. to a "strong-buy" rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. cut shares of Organon & Co. from a "neutral" rating to an "underweight" rating and increased their price target for the stock from $18.00 to $20.00 in a research report on Friday, September 6th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.